These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32163676)

  • 41. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneity of [
    Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
    Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C; Götz TI; Atzinger A; Ritt P; Prante O; Kuwert T; Bäuerle T; Goebell P; Cordes M
    Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
    Li L; Long Z; He L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 40(6):688-92. PubMed ID: 26164521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
    Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving
    Seifert R; Seitzer K; Herrmann K; Kessel K; Schäfers M; Kleesiek J; Weckesser M; Boegemann M; Rahbar K
    Theranostics; 2020; 10(17):7812-7820. PubMed ID: 32685021
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
    Su HC; Zhu Y; Ling GW; Hu SL; Xu XP; Dai B; Ye DW
    Asian J Androl; 2017; 19(3):267-271. PubMed ID: 27976632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
    Poon DMC; Wong KCW
    Clin Genitourin Cancer; 2018 Apr; 16(2):e397-e401. PubMed ID: 29174502
    [No Abstract]   [Full Text] [Related]  

  • 55. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Zhao F; Zhao J; Wei X; Shi Y; Xu N; Zhu S; Chen J; Sun G; Dai J; Wang Z; Zhang X; Liang J; Hu X; Liu H; Zhao J; Liu Z; Nie L; Shen P; Chen N; Zeng H
    Prostate; 2024 Jul; 84(10):932-944. PubMed ID: 38629249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
    Lin GW; Li GX; Dai B; Ye DW; Kong YY; Wang Y; Shen YJ
    Asian J Androl; 2019; 21(2):131-136. PubMed ID: 30560837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.
    Ke ZB; Chen JY; You Q; Sun JB; Xue YT; Ye XJ; Chen SH; Xue XY; Sun XL; Chen DN; Wei Y; Zheng QS; Chen SM; Xu N
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5071-5084. PubMed ID: 36333565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
    Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
    Bertaglia V; Tucci M; Vignani F; Buttigliero C; Aroasio E; Berruti A; Scagliotti GV; DI Maio M
    Minerva Urol Nefrol; 2017 Aug; 69(4):349-358. PubMed ID: 28008755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.